论文部分内容阅读
目的探讨恩度联合顺铂治疗恶性胸腔积液的疗效及对趋化因子表达的影响。方法选取2015年九江学院附属医院肿瘤科与呼吸科收治的恶性胸腔积液患者46例,随机分为对照组与试验组,各23例。对照组患者给予顺铂治疗,试验组给予顺铂+恩度治疗,两组均连续治疗2周。比较两组患者治疗效果、治疗前、治疗7周患者生活质量评分、胸腔积液量及毒副作用发生情况,观察患者胸腔积液CXCL-12及CXCR-4变化情况。结果试验组总有效率高于对照组,病变进展率低于对照组,差异有统计学意义(P<0.05)。两组患者均出现不同程度的毒副作用,经对症处理后全部好转。两组患者毒副作用发生率比较,差异无统计学意义(P>0.05)。治疗前两组患者CXCL-12、CXCR-4水平比较,差异无统计学意义(P>0.05);治疗后试验组患者CXCL-12、CXCR-4水平低于对照组,差异有统计学意义(P<0.05)。结论胸腔注入恩度联合顺铂治疗恶性胸腔积液是一种疗效确切、毒副作用少、可耐受的治疗方法,有利于提高患者生活质量,能够调节CXCL-12与CXCR-4的水平,提高患者化疗的效果。
Objective To investigate the effect of entecavir combined with cisplatin in the treatment of malignant pleural effusion and its effect on the expression of chemokines. Methods Forty-six patients with malignant pleural effusion admitted to Department of Oncology and Respiratory Diseases, Affiliated Hospital of Jiujiang University in 2015 were randomly divided into control group and experimental group, with 23 cases in each group. Patients in the control group were treated with cisplatin, and patients in the test group were given cisplatin + Endu treatment. Both groups were treated continuously for 2 weeks. The therapeutic effect, the quality of life score, the volume of pleural effusion and the side effects were compared between the two groups before treatment and 7 weeks after treatment. The changes of CXCL-12 and CXCR-4 in pleural effusion were observed. Results The total effective rate of the experimental group was higher than that of the control group, and the progress rate of the lesion was lower than that of the control group (P <0.05). Two groups of patients have varying degrees of toxic and side effects, all improved after symptomatic treatment. There was no significant difference in the incidence of side effects between the two groups (P> 0.05). There was no significant difference in CXCL-12 and CXCR-4 levels between the two groups before treatment (P> 0.05). After treatment, the levels of CXCL-12 and CXCR-4 in the experimental group were lower than those in the control group P <0.05). Conclusions Thoracic injection of endemic acid combined with cisplatin in the treatment of malignant pleural effusion is an effective treatment with few side effects and tolerability. It is beneficial to improve patients’ quality of life, and can regulate the levels of CXCL-12 and CXCR-4, The effect of chemotherapy in patients.